Abstract:Early- and late-phase estrogenic signaling in the uterus have been well recognized, yet molecular mechanisms involved in their relationships remain poorly understood. General consensus is that the early signals, occurring within the first 6 h, undergo appropriate molecular cross-talk to prepare the uterus for later (18-30 h) growth regulation. In this regard, GPR30 has been identified as a candidate of extra-nuclear receptor for estrogen and implicated in various early non-genomic signaling in both normal and cancer tissue biology. However, the genetic deletion of GPR30 in mice exhibited no apparent defects for estrogen-dependent uterine growth regulation. In contrast, here we show novel evidence to suggest that the uterine epithelial activation of GPR30 can elicit antagonistic signaling to the stroma to effectively modulate early signaling events, including the ERK1/2 activation for estrogen-dependent growth regulation. In our initial studies, we examined whether GPR30 activation can have any impacts to the uterus of ovariectomized mice. Consistent to the literature, we observed that an injection of GPR30 selective agonist, G-1 (at doses: 0.5, 2, 10, 50 or 100 µg/mouse) did not induce any significant alteration in uterine wet weights at 6 and 24 h, while an injection of estradiol-17β (E2, at doses 1, 5, 15, 25 or 100 ng/mouse) caused significant increase in uterine weights for both phases by doses ≥15-100 ng/mouse, suggesting G-1, as opposed to E2, lacks estrogenicity. In contrast, an injection of G-1 (at doses ≥25-100 µg/mouse) given 30 min prior to E2 (25 or 100 ng/ mouse) exhibited significant inhibition of E2-dependent uterine late response, while the early weight response remained unaffected. These results were further consistent with the analysis of E2-dependent uterine epithelial cell proliferation. To evaluate the mechanism involved in GPR30 mediated inhibitory role, we first examined the status of ERα and GPR30 expression under above conditions. Both mRNA and protein analyses indicate that E2 caused significant reduction of GPR30 levels, but not the ERα, during the early phase, while G-1 was unable to alter these proteins. Double immunofluorescence studies also show that GPR30 primarily co-expressed with ERα in uterine epithelial cells, while stroma primarily detected ERα. Further analysis of well-recognized early and late E2-responsive genes (viz., Bip, SFRP-2, c-fos, c-myc, cdkn1a and Ltf) revealed that expressional effects were either compromised or potentiated by G-1, suggesting G-1 modulates E2-regulated gene responses in the uterus. Additionally, analysis of several early non-genomic signaling events in respect of phosphorylation of ERK1/2, Akt (pThr308 and pSer473), CREB (pSer133) and ERα (pSer118) demonstrated that E2-dependent activation of ERK and ERα was predominantly suppressed by prior G-1 treatment, while Akt phosphorylation remained unaffected. In contrast, CREB phosphorylation was enhanced by such treatment. Most importantly, further studies using a selective ERK inhibitor (SL327) caused abrogation of E2-dependent uterine growth response, suggesting ERK activation critically controls E2-depedent uterine growth regulation. Collectively, our studies revealed that GPR30 acts as an upstream negative regulator for ERK activation that effectively controls uterine growth regulation under the direction of E2. (Supported by NIH grants ES007814 and HD056044). (poster)

Activation of G-Protein-Coupled Receptor, GPR30, Opposes Estrogenic Growth Regulation Via Inhibition of ERK1/2 Activation Signaling in the Mouse Uterus.